Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - olanzapine, quantity: 20 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; lactose monohydrate; purified talc; microcrystalline cellulose; hyprolose; titanium dioxide; xanthan gum; polyvinyl alcohol; lecithin; iron oxide yellow; iron oxide red; iron oxide black - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Bandaríkin - enska - NLM (National Library of Medicine)

american regent, inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 10 mg in 2 ml - olanzapine for injection is indicated for the treatment of acute agitation associated with schizophrenia and bipolar i mania. efficacy was demonstrated in 3 short-term (24 hours of intramuscular treatment) placebo-controlled trials in agitated adult inpatients with: schizophrenia or bipolar i disorder (manic or mixed episodes) [see clinical studies (14.3)]. “psychomotor agitation” is defined in dsm-iv as “excessive motor activity associated with a feeling of inner tension.” patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation. - none with olanzapine monotherapy. - for specific information about the contraindications of lithium or valproate, refer to the contraindications section of the package inserts for these other products. pregnancy expos

Evrópusambandið - maltneska - EMA (European Medicines Agency)

glenmark arzneimittel gmbh - olanzapine - schizophrenia; bipolar disorder - psikolettiċi - adultsolanzapine huwa indikat għall-kura ta ' skizofrenja. olanzapine hija effettiva biex iżżomm it-titjib kliniku waqt terapija kontinwa f'pazjenti li wrew rispons inizjali għat-trattament. olanzapine hu indikat għall-kura moderata għal severa ta ' episodju ta'manija. f'pazjenti li l-episodju ta'manija għandu rrispondew għat-trattament b'olanzapine, olanzapine hija indikata għall-prevenzjoni ta'rikorrenza f'pazjenti b'diżordni bipolari.

Holland - hollenska - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

synthon b.v. microweg 22 6545 cm nijmegen - olanzapinebenzoaat samenstelling overeenkomend met ; ; olanzapine 10 mg/stuk - tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460(i)) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat, calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468), - olanzapine

Holland - hollenska - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

synthon b.v. microweg 22 6545 cm nijmegen - olanzapinebenzoaat samenstelling overeenkomend met ; ; olanzapine 2,5 mg/stuk - tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460(i)) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat, calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468), - olanzapine

Holland - hollenska - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

synthon b.v. microweg 22 6545 cm nijmegen - olanzapinebenzoaat samenstelling overeenkomend met ; ; olanzapine 5 mg/stuk - tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460(i)) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat, calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468), - olanzapine

Holland - hollenska - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

synthon b.v. microweg 22 6545 cm nijmegen - olanzapinebenzoaat samenstelling overeenkomend met ; ; olanzapine 7,5 mg/stuk - tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460(i)) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat, calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468), - olanzapine

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - olanzapine, quantity: 20 mg - tablet, orally disintegrating - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; mannitol; magnesium stearate; aspartame; flavour - ? olanzapine is indicated for the treatment of schizophrenia and related psychoses. ? olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ? olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; mannitol; magnesium stearate; aspartame; flavour - ? olanzapine is indicated for the treatment of schizophrenia and related psychoses. ? olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ? olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - olanzapine, quantity: 10 mg - tablet, orally disintegrating - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; mannitol; magnesium stearate; aspartame; flavour - ? olanzapine is indicated for the treatment of schizophrenia and related psychoses. ? olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ? olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.